Teva Pushes CGRP Timeline Back To End Of 2018

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Management said the migraine drug fremanezumab could launch in the US by the end of the year following discussions with the US FDA. The June timeline has been delayed by a Celltrion manufacturing issue.

Binocular viewer_1200X675

Teva Pharmaceutical Industries Ltd. has pushed back the timeline for launching the migraine drug fremanezumab in the US, but still expects the CGRP drug could launch by the end of the year. Management updated investors on the expectations for the launch during a first quarter earnings call May 3 after previously warning the launch could be delayed due to a manufacturing issue at Celltrion Inc., which is manufacturing an active ingredient for fremanezumab.

In February, Teva said the issues at Celltrion could delay FDA action on fremanezumab beyond the June 16 user fee...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.